Revive Therapeutics Ltd.
RVVTF
$0.01
$0.00-9.09%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -86.21% | -92.13% | 7.51% | -22.06% | -12.06% |
| Total Depreciation and Amortization | -100.00% | -100.00% | -75.00% | -50.00% | -25.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 281.63% | 278.84% | 123.99% | 126.68% | 138.05% |
| Change in Net Operating Assets | 876.01% | 409.56% | 217.38% | 122.89% | 10.64% |
| Cash from Operations | 86.94% | 77.16% | 71.62% | 36.93% | 20.57% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 100.00% | -4,300.00% | 124.24% | -- | -- |
| Cash from Investing | 100.00% | -4,300.00% | 124.24% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | 86.75% | 32.03% | 6.34% | -19.63% |
| Issuance of Common Stock | -92.92% | -- | -96.51% | -53.29% | -53.29% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -144.41% | -100.00% | 91.91% | 107.98% | 123.94% |
| Cash from Financing | -90.82% | -98.19% | -98.92% | -51.65% | -51.65% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 81.33% | 43.03% | 38.57% | -13,752.94% | -321,733.33% |